NASDAQHealth CareDrug Manufacturers - Specialty & GenericSnapshot 2026-07-23
Reading TKNO? Create a free portfolio, then add this holding for ongoing Reports and tracking. Track it in a free portfolio. No credit card.
Create your account →A long-form read on the 1–3 year hold thesis. Slower and deeper than the daily snapshot — it refreshes only when the evidence moves.
This investment represents a turnaround play with a medium level of confidence. The company is currently loss-making but is working towards achieving specific revenue and margin targets over the next few years.
The current valuation reflects a durable premium compared to peers, indicating that the market has some expectations for future performance. However, there is a slight expectations gap, suggesting that the market may not fully account for the risks involved.
Management is on track to achieve its revenue guidance for 2026 and is making progress in improving gross profit margins. However, the company is facing high risk and has a significant free cash outflow that needs to be monitored closely.
The long-term thesis hinges on TKNO's ability to meet its revenue targets and maintain cash outflows. Additionally, the performance of sector bellwethers like HLN, TEVA, and ZTS will be crucial in determining the overall health of the Healthcare sector and TKNO's position within it.
In the next 1 to 3 years, TKNO's performance will depend on its execution of management priorities and external sector dynamics. Not investment advice.
The most important moves since the prior daily snapshot.
Our read on the company is unchanged since the prior snapshot.
as of 2026-07-23
Specific, dated things to watch for, each with what would confirm it and what would prove it wrong.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Why it matters: Earnings reports give important updates on revenue, cash flow, and margins.
Confirms one read:Earnings report shows good results. It exceeded revenue and margin expectations.
Confirms the other:Earnings report shows poor results. It missed revenue and margin expectations.
Why it matters: Meeting revenue goals shows strong business growth. This helps build investor trust.
Confirms:Q2 revenue reported between $10.5M and $11.5M, supporting the annual target.
Disproves:Q2 revenue was below $10.5M. This shows challenges in meeting yearly goals.
Why it matters: Meeting or exceeding this growth rate shows Teknova is on track to hit its annual revenue target.
Confirms:Q2 total revenue growth of 13% or more compared to Q2 2025.
Disproves:Q2 total revenue growth below 13% compared to Q2 2025.
Why it matters: Better margins mean Teknova is managing costs well and can make more money.
Confirms:Gross profit margin increases to above 34.2% in Q2 2026.
Disproves:Gross profit margin falls below 34.2% in Q2 2026.
Why it matters: Higher margins show better cost control. This can help increase profits.
Confirms:Gross profit margin was above 34% in Q2. This shows good cost control.
Disproves:Gross profit margin was below 34% in Q2. This indicates margin pressure.
Why it matters: A return to faster revenue growth would signal a positive shift in company momentum. This could improve investor confidence.
Confirms:Revenue growth re-accelerates back toward its previous highs of near 10%.
Disproves:Revenue growth is slowing down or remains below current levels.
Why it matters: Staying below this level shows Teknova is using its cash well while growing.
Confirms:Free cash outflow reported below $10 million for the first half of 2026.
Disproves:Free cash outflow exceeds $10 million for the first half of 2026.
Why it matters: The earnings report will show how Teknova is doing financially and its progress.
Confirms one read:Earnings report shows revenue and cash flow metrics meeting or exceeding guidance.
Confirms the other:The earnings report shows big misses on revenue or cash flow goals.
